This page shows the latest Almirall news and features for those working in and with pharma, biotech and healthcare.
Barcelona-based Almirall – which specialises in dermatology – says that the deal would expand its R&D pipeline with an additional three candidates on top of lead drug BNZ-1. ... Meanwhile, Almirall is in the launch phase for Ilumya/Ilumetri
It will inherit established partnerships that Nuevolution also signed with the likes of Almirall, and Johnson &Johnson, according to the Danish firm’s website, and analysts at Edison said in March ... The Almirall partnership includes a RORγt
And that’s exactly what comes out of my research. The recent industry announcement that triggered this thought was from Almirall, the Spanish pharma company with fewer than 2, 000 employees
In a deal worth $650m, Spanish pharmaceutical company Almirall is set to buy Allergan’s US-based medical dermatology unit. ... If approved, Seysara could pull in predicted annual sales of $200m for Almirall.
There was also good news for Almirall, which got the nod for its delayed interleukin-23 inhibitor Ilumetri (tildrakizumab) as a treatment for moderate to severe plaque psoriasis, although it enters
Last November, Sun Pharma’s European licensee for tildrakizumab - Spain’s Almirall - said it expects the launch of the drug in the EU to be delayed by at least six months ... Almirall licensed European rights to the drug in July 2016 and filed for
More from news
Approximately 10 fully matching, plus 65 partially matching documents found.
12. Symatese. Almirall. Development collaboration. Customised products in aesthetics. 8. AgaImmune.
510. Nuevolution (Denmark). Almirall (Spain). Research collaboration. RORγt inhibitors for inflammatory skin diseases and psoriatic arthritis. ... $21m plus $80m equity. Biosimilars. Nuevolution. Almirall. $453m. $11.8m. Inhibitors to transcription
$575m. $198m. 2.9. Respiratory 2014. Almirall. Products pipeline. $2, 100 milestones.
Celyad. $311m. $12.5m. Almirall. Patagonia. $28m. $3.5m. Petra Pharma. Sprint BioScience. ... Almirall's initial expenditure has been a more modest $3.5m for this earlier stage product.
Also speaking at the eyeforpharma conference was Almirall's CEO Eduardo Sanchiz, who noted that, while patient-centricity is often talked about in the industry, “we have difficulties putting it in
More from intelligence
Approximately 2 fully matching, plus 10 partially matching documents found.
Before that, he lead global R&D at Almirall, which involved 500 staff and the development and approval of several new drugs in a number of therapy areas.
Together with my team, I am convinced we will be able to fully unlock the value of Almirall.”. ... I am convinced he will bring what is needed to develop Almirall to the next level.”.
Pfizer. Eduardo Sanchiz, chief executive officer at Almirall, said: “We are very pleased to announce the appointment of Ron Menezes as the new president and GM of Aqua Pharmaceuticals. ... Sanchiz added: “Almirall continues to consider Aqua as a very
He will also serve as the Almirall-owned firm's general manager. Medical aesthetics technology firm ThermiGen has appointed Vladmir Paul-Blanc as its president and general manager. ... He said: “I couldn’t be more excitied to join Almirall and work
Most recently, Dr Connolly served as scientific leader with Almirall, based in Barcelona, Spain.
More from appointments
Approximately 5 fully matching, plus 5 partially matching documents found.
Strategic planning - to ensure ongoing engagement and success. Alexion, Almirall, Alnylam, AstraZeneca, Bial, Biogen, Bluebird Bio, Boehringer Ingelheim, BMS, CSL Behring, Ferring, Four Health, GSK, HRA Pharma, Janssen, Leo Pharma, Lilly,
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Our goal is to identify and embed transformational patient insights as a fundamental part of the drug development process. As...